CompletedPhase 2

MRX-I Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection

120 participantsStarted 2015-02

Plain-language summary

The purpose of this study is to determine whether MRX-I is as safe and effective as Linezolid in the treatment of adult patients with acute bacterial skin and skin structure infections

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with systemic signs of infection diagnosed with acute bacterial skin and skin structure infection (ABSSSI) * Diagnosed with Cellulitis/ erysipelas, major cutaneous abscess, or wound infections Exclusion Criteria: * Uncomplicated skin infections * Severe sepsis or septic shock * ABSSSI solely due to gram-negative pathogens * Prior systemic antibiotics within 96 hours of randomization

What they're measuring

Number of Patients at the Early Assessment Visit With a 20% Reduction in ABSSSI Lesion Size Compared to Baseline

Timeframe: 48-72 hours

Trial details

NCT IDNCT02269319

SponsorMicuRx

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2015-08

Results submitted2023-10-30

View on ClinicalTrials.gov More Bacterial Infections trials